MoonLake Immunotherapeutics (MLTX) — Research Snapshot as of 2026-10-31

Note: The following is a factual summary of publicly reported developments, not investment advice. Several sources below are algorithmically generated financial-commentary platforms that explicitly disclaim to provide advice.

Profile (quick reference)

MoonLake is a clinical-stage biopharmaceutical company headquartered in Zug, Switzerland, advancing sonelokimab, an investigational Nanobody-based therapy that inhibits IL-17A and IL-17F across inflammatory indications including hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and axial spondyloarthritis [10]. The company reports no revenue, has not paid a dividend, and trades on NASDAQ [10].

Recent catalysts (last ~1–3 months)